10 completed, 2 recruiting, 2 terminated, 1 not yet recruiting. 11 Phase 1, 7 Phase 2, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 11 | Completed 8, Terminated 2, Recruiting 1 |
| Phase 2 | 7 | Completed 3, Recruiting 2, Not yet recruiting 1, Terminated 1 |
| Early Phase 1 | 1 | Unknown 1 |
Follow Vaccines, DNA: new trials by email Literature Review of Vaccines, DNA trials Research Report on Vaccines, DNA
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluating the Safety and Immunogenicity of Polyvalent DNA and Recombinant gp120 Protein HIV Vaccine (PDPHV) in Healthy, HIV-uninfected Adults PDPHV Plasmid DNA Vaccines (env (A, B, C, A/E)/gag (C)), PDPHV Recombinant Protein Vaccines (gp120 (A, B, C, A/E)), Alhydrogel adjuvant - HIV Prevention | Phase 2 | Not yet recruiting | Worcester HIV Vaccine | 126 | 2026-09-01 | 2026-06-30 |
| Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer Oral DNA Vaccine - Triple Negative Breast Cancer | Phase 1 / Phase 2 | Recruiting | NEC Bio B.V | 28 | 2024-11-20 | 2026-05-26 |
| pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w/Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal Cancer DNA Vaccine, Human Papillomavirus Tumor Antigen Vaccine, Pembrolizumab - Metastatic Oropharyngeal Carcinoma, Recurrent Oropharyngeal Carcinoma | Phase 2 | Recruiting | Michael K. Gibson | 54 | 2023-07-26 | 2026-07-15 |
| Evaluating the Safety and Immunogenicity of Polyvalent DNA/gp120 HIV Vaccine in Healthy, HIV-uninfected Adults env (A,B,C,A/E)/gag (C) DNA Vaccine, gp120 (A,B,C,A/E) Protein Vaccine, GLA-SE adjuvant - HIV Infections | Phase 1 | Completed | Worcester HIV Vaccine | 42 | 2021-07-08 | 2024-04-09 |
| DNA Vaccination Against Neuroblastoma DNA vaccine, Salmonella oral vaccine, Lenalidomide - Relapsed Neuroblastoma | Early Phase 1 | Unknown | Belarusian Research Center for Pediatric Oncology, Hematology and Immunology | 12 | 2019-01-09 | 2022-03-02 |
| Evaluating the Safety and Immunogenicity of Env (A,B,C,A/E)/Gag (C) DNA and gp120 (A,B,C,A/E) Protein/GLA-SE HIV Vaccines, Given Individually or Co-administered, in Healthy, HIV-1-Uninfected Adults env (A,B,C,A/E)/gag (C) DNA Vaccine, gp120 (A,B,C,A/E) Protein Vaccine, Placebo - HIV Infections | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 60 | 2018-03-16 | 2022-04-25 |
| An Exploratory Safety and Immunogenicity Study of HPV16+ Immunotherapy VB10.16 in Women With HSIL; CIN 2/3) VB10.16 Immunotherapy (DNA vaccine) - High Grade Cervical Intraepithelial Neoplasia | Phase 1 / Phase 2 | Completed | Nykode Therapeutics ASA | 34 | 2015-08-01 | 2022-07-13 |
| Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer sipuleucel-T, DNA Vaccine - Prostate Cancer | Phase 2 | Completed | University of Wisconsin, Madison | 18 | 2013-05-20 | 2021-06-18 |
| Safety and Immunogenicity Study of AIDS Vaccine (Combined Use of DNA Vaccine and Recombinant Vaccinia Virus Tiantan) DNA vaccine, DNA vaccine prime with the addition of electroporation, rTV boost - AIDS | Phase 2 | Completed | National Center for AIDS/STD Control and Prevention, China CDC | 150 | 2012-08-01 | 2015-05-06 |
| Evaluating the Safety and Priming Response of an HIV Vaccine Regimen in Healthy, HIV-Uninfected Adults DNA-HIV-PT123, NYVAC-HIV-PT1, NYVAC-HIV-PT4 - HIV Infections | Phase 1 | Completed | HIV Vaccine Trials Network | 96 | 2012-08-01 | 2015-03-25 |
| Safety Study of HPV DNA Vaccine to Treat Head and Neck Cancer Patients DNA Vaccine, Cyclophosphamide - Head and Neck Cancer | Phase 1 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2 | 2012-04-01 | 2018-11-23 |
| Seasonal Influenza DNA Vaccine Prime With Trivalent Inactivated Vaccine (TIV) Boost Compared to TIV Alone DNA vaccine, TIV - Influenza | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 131 | 2011-12-01 | 2016-03-24 |
| Therapeutic Vaccination for Patients With HPV16+ Cervical Intraepithelial Neoplasia (CIN2/3) DNA vaccination, Gene gun vaccine, intramuscular vaccination - HPV16 Positive, Cervical Intraepithelial Neoplasia (CIN 2/3) | Phase 1 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 132 | 2009-09-01 | 2018-07-09 |
| Safety and Immune Response to Preventive HIV Immunization With Adenovirus Serotype 5 or 35 Vector DNA Vaccine, DNA Vaccine placebo, rAd35 - HIV Infections | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 192 | 2009-02-01 | 2021-10-14 |
| Thai Prophylactic HIV Vaccine Phase I Study pHIS-HIV-AE (DNA vaccine) prime and rFPV-HIV-AE (recombinant fowlpox virus boost) vaccine - HIV | Phase 1 / Phase 2 | Terminated | Kirby Institute | 8 | 2007-08-01 | 2012-06-13 |
| Safety and Immunogenicity of a Naked DNA-based Vaccine Therapy in Patients With Chronic Hepatitis B DNA vaccine - Chronic Hepatitis B | Phase 1 | Completed | Institut National de la Santé Et de la Recherche Médicale, France | 10 | 2001-02-01 | 2025-09-26 |
HIV Infections (4) · Acquired Immunodeficiency Syndrome (2) · Adenoviridae Infections (1) · Head and Neck Neoplasms (1) · Hepatitis B (1) · Hepatitis B, Chronic (1) · Influenza, Human (1) · Neuroblastoma (1) · Oropharyngeal Neoplasms (1) · Orthomyxoviridae Infections (1) · Prostatic Neoplasms (1) · Sexually Transmitted Diseases, Viral (1) · Triple Negative Breast Neoplasms (1) · Uterine Cervical Dysplasia (1)
National Institute of Allergy and Infectious Diseases (NIAID) (3) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2) · Worcester HIV Vaccine (2) · Belarusian Research Center for Pediatric Oncology, Hematology and Immunology (1) · HIV Vaccine Trials Network (1) · Institut National de la Santé Et de la Recherche Médicale, France (1) · Kirby Institute (1) · Michael K. Gibson (1) · NEC Bio B.V (1) · National Center for AIDS/STD Control and Prevention, China CDC (1) · Nykode Therapeutics ASA (1) · University of Wisconsin, Madison (1)
United States (9) · Germany (2) · Belarus (1) · China (1) · France (1) · South Africa (1) · Switzerland (1) · Thailand (1)
Barney S Graham, M.D., Ph.D. (1) · Conasagrie Nair, PhD, MD (1) · Cornelia L Trimble, MD (1) · Douglas McNeel, M.D., PhD (1) · Giuseppe Pantaleo, MD (1) · Hao Wu, M.D. (1) · Ian Frank (1) · Inna V Proleskovskaya, PhD, MD (1) · Jonathan Fuchs, MD, MPH (1) · Joseph Califano, MD (1) · Julie Ledgerwood, D.O. (1) · Kiat Ruxrungtham, MD PhD (1) · Michael Gibson, MD, PhD (1)
PMID 40190112, PMID 16310901, PMID 20090916, PMID 20864808, PMID 25950433, PMID 28131393, PMID 29534736, PMID 31601541, PMID 34843602, PMID 36129459, PMID 38692824, PMID 41212034
P50CA098252 (1), P50DE019032 (1), R21CA128232 (1)